U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H21NO.C7H6O3
Molecular Weight 393.4764
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIPHENHYDRAMINE SALICYLATE

SMILES

CN(C)CCOC(c1ccccc1)c2ccccc2.c1ccc(c(c1)C(=O)O)O

InChI

InChIKey=RTSZUSOHOIFYSY-UHFFFAOYSA-N
InChI=1S/C17H21NO.C7H6O3/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;8-6-4-2-1-3-5(6)7(9)10/h3-12,17H,13-14H2,1-2H3;1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C17H21NO
Molecular Weight 255.3554
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Diphenhydramine is an antihistamine which is used in the combination with naproxen sodium for the relief of occasional sleeplessness when associated with minor aches and pains. Diphenhydramine has a role nighttime sleep-aid and naproxen sodium is a pain reliever. In addition, diphenhydramine used in relieving symptoms in patients with moderate-to-severe seasonal allergic rhinitis. Diphenhydramine acts as an antagonist of histamine H1 receptor. Besides, was shown potential to repurpose diphenhydramine as an anti-melanoma therapeutic agent, it induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling pathway.

Originator

Curator's Comment:: Diphenhydramine was discovered by George Rieveschl, in 1943 at the University of Cincinnati

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35367
Gene ID: 3269
Gene Symbol: HRH1
Target Organism: Homo sapiens (Human)
7.90000000000000036 null [pKi]
2.70000000000000018 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ALEVE PM

Approved Use

for relief of occasional sleeplessness when associated with minor aches and pains; helps you fall asleep and stay asleep

Launch Date

1389830400000
Palliative
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
93 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: UNKNOWN
age: ADOLESCENT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
667 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
887 ng × h/mL
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.2 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.5 h
50 mg single, intravenous
dose: 50 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
18.3%
DIPHENHYDRAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unknown, 13 months
Health Status: unknown
Age Group: 13 months
Sex: F
Sources:
Other AEs: QT interval prolonged...
Other AEs:
QT interval prolonged (1 patient)
Sources:
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Disc. AE: Liver injury, Vomiting...
AEs leading to
discontinuation/dose reduction:
Liver injury (1 patient)
Vomiting (1 patient)
Jaundice (1 patient)
Sources:
50 mg single, intravenous
Dose: 50 mg
Route: intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Hypertension...
Other AEs:
Hypertension (below serious, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
QT interval prolonged 1 patient
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unknown, 13 months
Health Status: unknown
Age Group: 13 months
Sex: F
Sources:
Jaundice 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Liver injury 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Vomiting 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 28 years
Health Status: unhealthy
Age Group: 28 years
Sex: M
Sources:
Hypertension below serious, 5 patients
50 mg single, intravenous
Dose: 50 mg
Route: intravenous
Route: single
Dose: 50 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak [IC50 11 uM]
yes (co-administration study)
Comment: diphenhydramine coadministration significantly altered the pharmacokinetics, heart rate, systolic blood pressure, and peak acceleration response of metoprolol in extensive metabolizers but not in poor metabolizers
yes [IC50 15 uM]
yes [IC50 3.4 uM]
yes [IC50 695 uM]
yes [Ki 266.5 uM]
yes [Ki 87 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
major
minor
minor
minor
minor
no
no
no
weak
weak
weak
weak
weak
weak
weak
PubMed

PubMed

TitleDatePubMed
Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).
1985 Nov-Dec
Diphenhydramine.
1986 Feb
Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children.
1990 Jul
Evaluation of diphenhydramine in talc induced type 2 diabetes mellitus in Wistar rats.
2018 Jan
A patient with anaphylaxis to diphenhydramine without cross-reactivity to loratadine.
2018 May - Jun
Patents

Patents

Sample Use Guides

occasional sleeplessness: do not take more than directed; drink a full glass of water with each dose, adults and children 12 years and over: take 2 caplets at bedtime, do not take more than 2 caplets in 24 hours, if taken with food, this product may take longer to work
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:50:46 UTC 2021
Edited
by admin
on Sat Jun 26 03:50:46 UTC 2021
Record UNII
707L3YC54L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPHENHYDRAMINE SALICYLATE
JAN   WHO-DD  
Common Name English
ZERESMIN
Brand Name English
BENADINE
Brand Name English
DIPHENHYDRAMINE SALICYLATE [WHO-DD]
Common Name English
DIMEDROL HYDROSALICYLATE
Brand Name English
BENZOIC ACID, 2-HYDROXY-, COMPD. WITH 2-(DIPHENYLMETHOXY)-N,N-DIMETHYLETHANAMINE (1:1)
Common Name English
DIPHENHYDRAMINE SALICYLATE [JAN]
Common Name English
ETHANAMINE, 2-(DIPHENYLMETHOXY)-N,N-DIMETHYL-, 2-HYDROXYBENZOATE
Systematic Name English
Code System Code Type Description
EVMPD
SUB01774MIG
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
FDA UNII
707L3YC54L
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
ECHA (EC/EINECS)
231-309-0
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
DRUG BANK
DBSALT000057
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
EPA CompTox
7491-10-3
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
CAS
7491-10-3
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
PUBCHEM
24098
Created by admin on Sat Jun 26 03:50:46 UTC 2021 , Edited by admin on Sat Jun 26 03:50:46 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY